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Abstract 
Purpose: To develop peptide-dendrimer-paclitaxel conjugates for the treatment of heterogeneous stage 
1 non small cell lung cancer (NSCLC) in 293T and L132cell line. 
Method: Dendrimer-paclitaxel conjugates (PAMAM-PTX) were prepared by NHS method and the 
conjugates were used for the synthesis of peptide-dendrimer-paclitaxel conjugates (GE-PAMAM-PTX). 
The particle sizes of PAMAM-PTX and GE-PAMAM-PTX were measured. Entrapment efficiency of PTX 
in PAMAM-PTX was measured while GE-PAMAM-PTX. PTX release from PAMAM-PTX and GE-
PAMAM-PTX was determined using a dialysis bag in pH 7.4 phosphate buffer. The cytotoxicity of 
PAMAM-PTX, GE-PAMAM-PTX, PAMAM and PTX was evaluated by 3-(4,5-dimethylthiazol-2-Yl)-2,5-
diphenyltetrazolium bromide (MTT) assay using 293T cell lines. In vitro cellular uptake assay of 
PAMAM-PTX and GE-PAMAM-PTX and PTX at concentrations ranging from 0.01 to 0.5µM for 8 h was 
carried out in NSCLC cell lines 293T and L132. 
Results: More than 95 % entrapment efficiency of GE-PAMAM-PTX was observed with loading 
efficiency of 25 %. GE-PAMAM-PTX conjugates showed sustained release of PTX (~85 %) towards the 
end of 50 h. GE-PAMAM-PTX conjugates were more cytotoxic than pure PTX and PAMAM-PTX 
conjugates. The remarkable uptake of GE-PAMAM-PTX appear to be due to receptor-mediated 
endocytosis in the cell lines. The presence of ligand (GE) on PAMAM-PTX surface enabled the complex 
to bind to the over-expressed receptors on the cell lines. 
Conclusion: GE-PAMAM-PTX can facilitate targeting of paclitaxel to lung cancer cell lines and tumors 
and facilitate release of the drugs in a sustained manner to improve the therapeutic efficacy of PTX.  
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Lung cancer is also known as pulmonary 
carcinoma. Lung cancer is characterized by the 
uncontrolled growth of cells in the tissues of lung. 
In developed and under developed countries 
nearly 25 % deaths are due to cancer among 
which lung cancer is found as a major cause of 
mortality [1]. Lung cancers can be broadly 
divided in to small cell lung carcinoma (SCLC) 
and non-small cell lung carcinoma (NSCLC). It 
has been found that about 85 – 90 % of lung 
cancer patients are histologically diagnosed with 
NSCLC [2,3]. Currently, chemotherapy, surgery, 
radiation therapy or combinations of these are 
the best treatment options for patients suffering 
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from NSCLC. Among these available treatment 
options chemotherapy and radiation therapy has 
very little success rate for the treatment of 
NSCLC [4]. Unfortunately, presently available 
treatment options have limited tumor killing 
potential and also suffer from serious systemic 
toxicity. The major problem associated with 
current chemotherapy is nonspecific tumor 
targeting that kills normal cells as well severe 
side effects in patients with NSCLC [5]. 
 
Polyamidoamine (PAMAM) dendrimers are found 
to be potential drug carrier in cancers targeted 
drug delivery system. Dendrimers are widely 
applied in drug delivery technology due to their 
excellent monodispersed, hyper branched, three 
dimensional, tree like host-guest entrapment 
properties Dendrimers are extensively used in 
pharmaceutical, biotechnological applications to 
deliver biomolecules [6]. PAMAM dendrimers can 
be easily modified at the terminal amine groups 
by acetylation or PEGylation so as to improve 
their specific targeting to tumor cells [7]. 
  
Over expression of epidermal growth factor 
receptor (EGFR) of about 40 to 80 % has been 
detected in NSCLC. GE11 is a peptide with high 
affinity for overexpressed EGFR tumor cells [8]. 
Specific targeting capability of PAMAM 
dendrimers can be improved by various targeting 
molecules such as folic acid, biotin, antibodies, 
peptides and carbohydrates [9-11]. Liu et al 
successfully developed peptide dendrimer 
conjugates as drug carriers for NSCLC [12]. Also 
Cheng et al developed GEII modified liposomes 
for NSCLC targeting [13]. Apart from this, Long 
et al have developed doxorubicin encapsulated 
EGF surface modified gelatin nanoparticles to 
target EGFR overexpressed in lung cancer tissue 
[14]. In the present study we have used 
paclitaxel (PTX) as a model anticancer drug 
which is a first line chemotherapeutic agent that 
works by disrupting normal microtubule 
breakdown while the cell divides. The major 
difficulty with the drug is that it is poorly soluble in 
water. Therefore, it is necessary to develop an 
alternate delivery system for PTX with the aim of 
increasing its availability and maximize its 






Paclitaxel was obtained from Afine Chemicals 
Limited, China. Acetylated PAMAM G3 
dendrimer was procured from Sigma Aldrich, 
USA. GE11 peptide with terminal cysteine was 
procured from GL Biochem Ltd (Shanghai, 
People’s Republic of China). 
Preparation of dendrimer-paclitaxel 
conjugates (PAMAM-PTX) 
 
The synthesis of dendrimer-paclitaxel conjugate 
was as described by Teow et al. Covalent 
attachment of lauryl chains to the surface of 
dendrimers (PAMAM G3) was done by activating 
lauryl chain to lauryl 4-nitrophenyl carbonate. 
The lauryl 4-nitrophenyl carbonate was reacted 
with amine groups of dendrimers present on the 
terminal surface (PAMAMG3 at the appropriate 
molar ratio) to obtain lauryl-G3PAMAM 
dendrimers. The N-hydroxysuccinimide (NHS) 
method (through a glutaric anhydride linker) was 
used to form paclitaxel lauryl-G3 PAMAM 
dendrimer conjugate. Paclitaxel was reacted with 
glutaric anhydride to produce 2’-glutaryl-
paclitaxel. Then it was converted to paclitaxel-
glutaryl-NHS ester, followed by equimolar 
conjugation with lauryl-G3 PAMAM dendrimers to 
produce PAMAM-PTX conjugates [16]. 
 
Synthesis of peptide-dendrimer-paclitaxel 
conjugates (GE-PAMAM-PTX): 
 
GE11 peptide with terminal cysteine (9.2 mg) 
was dissolved in 1.5 mL DMSO solution and it 
was added drop wise to the solution containing 
dendrimer –paclitaxel conjugates (PAMAM-PTX). 
The solution was stirred overnight on magnetic 
stirrer and the crude product was dialyzed using 
dialysis membrane (molecular weight cut off = 
3500 Da).Removal of peptide was ensured by 
measuring absorbance at 280 nm. The product 
obtained was lyophilized in a dark room for 24 h 
to yield free-flowing powder of peptide-




The particle size of PAMAM-PTX and GE-
PAMAM-PTX was measured in a Zetasizer 
(Malvern instruments DTS Ver 4.10).  
 
PTX conjugation efficiency (CE) 
 
The PAMAM-PTX and GE-PAMAM-PTX were 
centrifuged separately and the amount of non-
conjugated PTX (free drug) was measured in the 
clear supernatant using HPLC. Conjugation 
efficiency (CE) of the PTX from PAMAM-PTX 
and GE-PAMAM-PTX were calculated as in Eq 1 
[13]. 
 
% C.E = {(Td – Fd)/Td}100 ………………. (1) 
 
Where Td and Fd are the total and free 
(unconjugated) drug, respectively. 
 
In vitro PTX release study 
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PTX release from PAMAM-PTX and GE-
PAMAM-PTX was determined using dialysis bag 
with magnetic stirring. PAMAM-PTX and GE-
PAMAM-PTX conjugates (15 mg) were dispersed 
separately in 5 mL pH 7.4 phosphate buffer and 
placed in a dialysis membrane bag tied on both 
ends and placed into 200 mL PBS solution in a 
beaker. The temperature was maintained at 37 
oC and whole system was kept on magnetic 
stirring. At specified time interval, 5 ml of buffer 
solution was removed and replenished with fresh 
PBS solution to maintain the sink condition [16]. 
The amount of PTX in released into the medium 




NSCLC cell line 293T and L132 were purchased 
from Shanghai Institute of Cell Biology. Both cell 
lines were cultured in Roswell Park Memorial 
Institute-1640 (RPMI-1640) supplemented with 
10 % fetal bovine serum, 1 % penicillin and 100 




The cytotoxicity of PAMAM-PTX and GE-
PAMAM-PTX, PAMAM and PTX was evaluated 
by MTT assay. 293T cells were seeded (at a 
density of 1 x 105 cells/well) into 96-well plates 
and incubated for 24 h. The cells were incubated 
for 24 h with the test compound (PAMAM-PTX, 
GE-PAMAM-PTX, PAMAM and PTX) at 0.20 and 
0.40 mg/mL concentrations. Thereafter, 1 mg/mL 
MTT was added and incubated for 1 h with the 
treated human lung cancer cell line 293T at 37 
oC. Amount of MTT converted to insoluble 
formazan dye by mitochondrial dehydrogenases 
determines the viable cells. The formed 
formazan crystals were dissolved in a 1 M HCl-
isopropyl alcohol mixture (1:24 v/v) and shaken 
for 20 min at room temperature [13]. 
 
In vitro cellular uptake assay in NSCLC cell 
line 293T and L132 
 
Cell culture 24 well plates were used to seed 
293T and L132 cells (density of 105 cells/well). 
The cells were incubated with PAMAM-PTX, GE-
PAMAM-PTX and PTX at concentrations of 0.01 
to 0. 5 µM for 8 h. A 0.5 µM concentration of 
conjugate was used for incubation of the cells for 
4 h, to compare the uptake efficiency between 
293T and L132 cells. The cells were trypsinised 
at the end of incubation and washed with saline 
buffer three times. They were then centrifuged 
and treated with lysis buffer and sonicated. The 
internalized drug was quantified by measuring 




The particle size analysis of both PAMAM-PTX 
and GE-PAMAM-PTX was determined by using 
Zetasizer (Malvern Instruments DTS, Ver 4.10). 
No significant difference was found between 
particle size of PAMAM-PTX and GE-PAMAM-
PTX. The particle size of PAMAM-PTX and GE-
PAMAM-PTX was 110 and 112.5 nm, 
respectively. Furthermore, entrapment efficiency 
of both PAMAM-PTX and GE-PAMAM-PTX were 
more than 95 % with effective loading efficiency 
of 25 %.Release of PTX from PAMAM-PTX and 
GE-PAMAM-PTX was done in phosphate 
buffered saline (pH 7.4). As can be seen in 
Figure 1, ~100 % unconjugated PTX was release 
within 10 h while initial rapid  release of ~15 % 
was observed from both PAMAM-PTX and GE-
PAMAM-PTX conjugated system, followed by 
gradual sustained release of PTX (~85 % in 50 
h). 
 
In vitro cytotoxicity data for human lung cancer 
cell line (Figure 2), indicate concentration-
dependent cytotoxicity in 24 h. 
 
Cellular uptake results show that cellular uptake 
efficiencies of PTX and PAMAM-PTX were 
concentration-dependent for both cell lines, as 
shown in Figure 3. Uptake efficiency of GE-
PAMAM-PTX was much higher than that of PTX. 
PAMAM-PTX also showed 2.5 fold higher cellular 





Figure 1: Comparative drug release profile of 
PAMAM-PTX, GE-PAMAM-PTX and PTX. No 
significant difference was observed between PAMAM-
PTX, GE-PAMAM-PTX indicating conjugation of 
peptide did not alter the release pattern of PAMAM-
PTX
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       Figure 3: In vitro cellular uptake assay study on L132 cell line and 293T cell line 
 
 
Figure 2: In vitro cytotoxic assay carried out in human 




Smaller particle size of the carrier system plays 
vital role in distribution in cell culture and that 
leads to maximum cellular accumulation of drug. 
It is a well-known fact that smaller particles have 
maximum capacity to invade the lung tumour. 
The results indicate that addition of GE11 
peptide on PAMAM-PTX conjugate did not alter 
the particle size distribution characteristics. The 
maximum entrapment efficiency of PTX was 
attributed to empty internal cavities of the 
dendrimer which easily accommodate the 
hydrophobic drug molecule in the macromolecule 
interior. PTX is a highly hydrophobic molecule 
which was successfully entrapped in the internal 
cavities of the PAMAM dendrimer [17]. The 
sustained release system used played an 
important role for availability of PTX in constant 
and steady manner to lung tumor. The drug 
release kinetics was studied by applying 
mathematical models like zero order, first order, 
Higuchi and Koremeyer- Peppas model. Out of 
these four models, Higuchi model (r = 0.992) was 
found to be the best fit indicating diffusion based 
drug release pattern. Koremeyer-Peppas which 
is a semi-empirical formula was used to describe 
the drug release mechanism. The ‘n’value of 
0.84 confirms the non-Fickian mode of release 
which suggests diffusion and erosion are the 
main mechanisms of action [18]. 
 
GE-PAMAM-PTX exhibited the greatest anti-
proliferative effect in this cell line as compared to 
that of PTX, PAMAM-PTX. Enhancement of anti-
proliferative effect of GE-PAMAM-PTX is 
attributed to enhanced cellular uptake. The 
conjugate system following endocytic uptake will 
rapidly escape from the endocytic compartments 
and reach the acidic lysosome. In this acidic 
environment PTX will be released continuously in 
a steady manner and diffuses into nuclear core 
complex. PTX works by disrupting the normal 
microtubule breakdown while the cell divides 
[19]. It is very essential to internalize 
nanoparticles into cancerous cells so that the 
drug will be released and is available for 
therapeutic action. However, the uptake capacity 
of the GE-PAMAM-PTX was much higher than 
that of PTX, and PAMAM-PTX, demonstrating a 
2.5-fold higher cellular internalization. The 
remarkable uptake of GE-PAMAM-PTX is due to 
endocytosis mediated by receptors. The 
presence of ligand (GE) on PAMAM-PTX surface 
enabled the complex to bind to the over-
expressed receptors on the cell lines. The 
remarkable lower cellular uptake observed for 
PTX, and PAMAM-PTX was due to non-specific 





conjugates have been successfully developed to 
target epidermal growth factor receptor (EGFR) 
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which are over-expressed in lung cancer tissue. 
The remarkable uptake of GE-PAMAM-PTX 
observed may be due to receptor-mediated 
endocytosis in the cell lines (L132 cell line and 
293T cells). The presence of ligand (GE) on 
PAMAM-PTX surface enables the complex to 
bind to the over-expressed receptors on the cell 
lines. Overall, the results show that GE-PAMAM-
PTX can facilitate drug targeting to lung cancer 
cell line and tumors in a sustained manner and 
thus, improve the therapeutic efficacy of PTX. 
This targeted drug delivery system appears 
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